Zymeworks Inc (ZYME) CEO Sells $48,720.00 in Stock

Zymeworks Inc (NYSE:ZYME) CEO Ali Tehrani sold 3,000 shares of the business’s stock in a transaction on Friday, March 29th. The shares were sold at an average price of $16.24, for a total transaction of $48,720.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

NYSE ZYME traded up $0.55 on Friday, reaching $16.05. The company’s stock had a trading volume of 142,695 shares, compared to its average volume of 100,113. The company has a market capitalization of $514.00 million, a price-to-earnings ratio of -12.74 and a beta of 1.48. Zymeworks Inc has a twelve month low of $10.72 and a twelve month high of $29.00.

Zymeworks (NYSE:ZYME) last posted its quarterly earnings data on Wednesday, March 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.19. The firm had revenue of $28.93 million for the quarter, compared to the consensus estimate of $65.00 million. Zymeworks had a negative return on equity of 23.17% and a negative net margin of 68.95%. On average, sell-side analysts anticipate that Zymeworks Inc will post -2.37 EPS for the current year.

Several equities analysts have recently issued reports on ZYME shares. Zacks Investment Research raised shares of Zymeworks from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a report on Friday, March 29th. ValuEngine raised shares of Zymeworks from a “hold” rating to a “buy” rating in a report on Monday, January 7th. TheStreet raised shares of Zymeworks from a “d” rating to a “c-” rating in a report on Friday, January 11th. Finally, Raymond James set a $29.00 price objective on shares of Zymeworks and gave the stock an “outperform” rating in a report on Thursday, March 14th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $23.43.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Montreal Can raised its holdings in Zymeworks by 17.9% during the 4th quarter. Bank of Montreal Can now owns 4,380 shares of the company’s stock worth $64,000 after buying an additional 665 shares during the period. K.J. Harrison & Partners Inc raised its holdings in Zymeworks by 25.0% during the 4th quarter. K.J. Harrison & Partners Inc now owns 15,000 shares of the company’s stock worth $219,000 after buying an additional 3,000 shares during the period. SG Americas Securities LLC acquired a new stake in Zymeworks during the 4th quarter worth about $225,000. Jane Street Group LLC acquired a new stake in Zymeworks during the 4th quarter worth about $1,127,000. Finally, Fosun International Ltd acquired a new stake in Zymeworks during the 4th quarter worth about $1,030,000. Hedge funds and other institutional investors own 28.37% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Zymeworks Inc (ZYME) CEO Sells $48,720.00 in Stock” was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/21/zymeworks-inc-zyme-ceo-ali-tehrani-sells-3000-shares.html.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors.

Featured Story: How to find the components of the quick ratio

Insider Buying and Selling by Quarter for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.